Group items tagged

A new study has underscored the significance of offering customers a variety of payment choices, particularly as digital platforms gain popularity among younger age groups. Almost one in three (30 per cent) people surveyed by payments solutions provider, Access PaySuite reported a negative experience when purchasing health and wellbeing products or services due to limited payment options. The research showed that online and in-person cash payments were the most preferred modes of payment, while more than a quarter of consumers expressed their preference for paying through Direct Debit. About 17 per cent of the participants favoured using a mobile app for payments during the booking process, followed by mobile in-person options like Google Pay (14 per cent) and phone-based transactions using debit or credit card) (13 per cent).

More than 10,000 pharmacy contractors those have declared their March FP34C submission figures through the Manage Your Service (MYS) portal by 5 April will receive earlier advance payments on Monday 11 April, the NHS Business Services Authority (NHSBSA) announced. Around 10,700 pharmacy contractors have made their submissions through MYS portal. They will receive their advance payments some 20 days earlier than the normal payment timetable. However, due to late submission (after April 5), over 500 contractors will not receive any earlier advance payments in April. These contractors will receive their advance payments on 1 May, in accordance with the normal payment timetable. From this month, MYS is the only route available to contractors for all monthly FP34C submissions. The Pharmaceutical Services Negotiating Committee (PSNC) reminded contractors that from this month (for prescriptions dispensed in March), the NHSBSA may apply an administrative deduction of £25 if a prescription bundle is submitted late.

Nearly 9,000 pharmacy contractors benefitted from earlier advance payment in January, Pharmaceutical Services Negotiating Committee (PSNC) said in an update. Contractors who declared their December FP34C submission figures (for the dispensed prescriptions) through the Manage Your Service (MYS) portal by January 6, would have received earlier advance payments on January 12. Meanwhile, all contractors who made submissions after January 6 or used the FP34C paper document, will receive payments as per the normal payment schedule i.e. on February 1, 2022. PSNC encouraged contractors to submit their monthly declaration through the MYS portal by the 5th of the month to avail early payments.

More than 9,300 pharmacy contractors would benefit from earlier advance payment in February, Pharmaceutical Services Negotiating Committee (PSNC) said in an update. Contractors who declared their January 2022 FP34C submission figures through the Manage Your Service (MYS) portal by February 5 will receive earlier advance payments by today (February 10). The statistics indicates nearly 2,000 contractors will not receive any earlier advance payment this month, either because their January declarations were submitted late or they used the paper FP34C submission document to make their declaration, PSNC said. These contractors will receive their advance payments in accordance with the normal payment timetable i.e. on March 1. The negotiator reminded contractors that from April 2022 MYS will be the only process to make monthly submissions.

The Pharmaceutical Services Negotiating Committee (PSNC) has reminded community pharmacy contractors that they have two weeks left to claim an Aspiration payment for the Pharmacy Quality Scheme (PQS) 2022/23. The window for claiming the payment will close at 11.59pm on 4 November 2022. "The Aspiration payment is optional; if contractors do not want to claim it, it will not impact on the contractor's ability to claim a PQS payment during the declaration period. There is also no requirement to have claimed for a previous PQS to claim an Aspiration payment for PQS 2022/23," said PSNC.

The Pharmaceutical Services Negotiating Committee (PSNC) has refused to accept the Department of Health and Social Care (DHSC)'s decision to get rid of 'transitional payments' from February 2023. The pharmacy negotiator said that 'any reductions in payments at this point will be impossible for community pharmacy contractors to manage financially.' "We are also continuing to be clear with officials and ministers that CPCF funding needs an urgent uplift to help businesses to cope with soaring costs being driven by inflation and the workforce crisis. We put a comprehensive business case to the government for this uplift in the last CPCF negotiations." The latest 'transitional payments decision' by the Department follows the announcement last year that the value of the these payments would be phased down over the second half of 2022/23 and will be based on the latest monitoring and analysis of funding delivery. PSNC says it submitted a fully-costed bid for a 'Pharmacy First' service in its last round of negotiations alongside the case for an uplift to core CPCF funding. Both of these were refused.

The Pharmaceutical Services Negotiating Committee (PSNC) has reminded community pharmacy contractors to start working on the quality criteria if they intend to meet the Respiratory domain of the Pharmacy Quality Scheme (PQS) 2022/23. For respiratory domain, community pharmacy contractors  must start working towards inhaler waste management; use of a spacer in patients aged 5-15 years; and personalised asthma action plans, from today (10 October). Resources are also available to support contractors with meeting the above criteria on the PQS hub page. PSNC also informed that contractors are also now able to make a claim for an Aspiration payment for the PQS 2022/23 on the NHS Business Services Authority (NHSBSA)  Manage Your Service (MYS) portal. "The Aspiration payment is optional; if contractors do not want to claim it, it will not impact on the contractor's ability to claim a PQS payment during the declaration period. There is also no requirement to have claimed for a previous PQS to claim an Aspiration payment for PQS 2022/23.

The new Flat Fee payment to roll out in April 2023 to all pharmacy contractors who dispense at least 101 items a month, up to a national total of £70m on an annual basis. "The value of the Flat Fee payment has now been determined at £533 per month and will be introduced in the April 2023 Drug Tariff," said the Pharmaceutical Services Negotiating Committee (PSNC). "As with all payments, the Flat Fee payments are subject to change throughout the year depending on the overall level of funding delivery to Community Pharmacies. This will be carefully monitored by PSNC and DHSC, and any funding changes will be communicated to pharmacy contractors as soon as they are known," said PSNC.

The Pharmaceutical Services Negotiating Committee (PSNC) has announced the margin delivery rates will increase from October as the agreed £100m write off is implemented. "The baseline margin allowance will remain £800m per year in 2022/23 and 2023/24," said PSNC. "Margin levels in the last two full years (2020/21 and 2021/22), as measured by the Margin Survey of independent pharmacies, were in excess of the baseline allowance, meaning that an excess was accrued." As new services have been introduced and take up of these has accelerated, the amount of unallocated funding left in the CPCF is now less than it previously was. As such, the value of the Transitional Payments will decrease from its current level. Some of the unallocated funding remaining in 2023/24 will be repurposed into a Flat Payment for all contractors (see details below). Over the course of the second half of 2022/23, the value of the Transitional Payments will be phased down. This will start in October 2022 with a reduction in payment levels to approximately 85% of the current level, as shown in the following table:

Community pharmacy contractors eligible under the revised Pharmacy Access Scheme (PhAS) will receive their first of the new monthly payments with the January reconciliation payment due on April 1, 2022. Details of the revised version of the PhAS that commenced from January 1, was published in August 2021, with contractors receiving letters from the NHS Business Services Authority (NHSBSA) indicating their eligibility in the Autumn, PSNC said in an update. Payments under the scheme are dependent on registration on NHSBSA's Manage Your Service (MYS) portal to provide the Community Pharmacist Consultation Service(CPCS). Meanwhile, the review application window is now open for contractors, which would enable the NHS England and NHS Improvement (NHSE&I) to correct inaccuracies related to a pharmacy's distance criteria/calculation.

Thousands of people in Britain infected with HIV and hepatitis C through contaminated blood transfusions will receive a compensation payment decades after the scandal, the government announced on Wednesday (August 17). The payment of £100,000 ($121,000) to each victim is an interim one after Brian Langstaff, the chairman of a public inquiry into the long-running scandal, last month recommended making immediate payouts before waiting for an ongoing inquiry to conclude. The former High Court judge said that the "moral case for compensation is beyond doubt". The government said the tax-free payments, to survivors of the scandal and bereaved partners of the thousands estimated to have died from the contaminated blood, would be made by the end of October. Thousands of people with haemophilia contracted hepatitis C and HIV after receiving blood transfusions, mainly from the United States, through the NHS in the 1970s, 1980s and 1990s. Due to a shortage of blood products in Britain, the NHS bought much of its stock from US suppliers whose donors, including prisoners and other groups at high risk of infection, had been paid for their blood.

Community Pharmacy England (CPE) is aiming to reach an agreement with the Department of Health and Social Care (DHSC) and NHS England (NHSE) on negotiation with regards to expanded services and payment model in the pharmacy sector. Chief Executive Janet Morrison, said: "We are working at pace in negotiations with DHSC and NHSE. The process remains on track with the Government's original timescale - i.e. aiming for agreement in July, with cross-government clearance later in July, and implementation from July through to September." CPE is involved in working groups on service expansion of Hypertension Case-Finding and the Pharmacy Contraception Scheme and service design for the Common Conditions Service; and are in in-depth negotiations on Payment models. These discussions critically look at the balance between funding core capacity and activity payments, how the funding streams will be distributed and how CPE will measure delivery and impact. NHSE has been leading on the development of the PGD pathways for each of the 7 conditions, with external medical, pharmacy and other experts feeding into the process - pharmacy owners from the Community Pharmacy England Committee have also been involved but the discussions are clinically led to ensure they comply with NICE principles and concur with Antimicrobial Stewardship policy.

The Federation of Small Businesses (FSB) on Thursday (4 December) announced a new strategic partnership with the Bank of England to protect small businesses from the risks associated with accepting counterfeit banknotes. Cash is still the number one customer payment method for 25 per cent of small high street businesses, and cash payments are expected to increase during the festive period, according to FSB. By becoming a Strategic Partner of the Bank of England's Banknote Checking Scheme, the organisation is trying to help its members become aware of the use of counterfeit notes, which has reputational and financial impacts. The FSB is encouraging its members to sign up to the Scheme, which offers training materials to staff so they can identify a counterfeit note at point of sale and know what to do with it, as well as stay up to date with best practice and bank note developments.

Surrogacy itself calls up a lot of moral and ethical concerns, mostly because of the money that is involved. Also the fact that a childless couple are asking, sometimes, a complete stranger to become pregnant for them and then give them the child after the birth. Depending on the infertility problems of the intended couple, the surrogate mother will become pregnant in some very different ways. Firstly there is the traditional method, which is where the intended fathers sperm is used to artificially inseminate the surrogate mother. This is using the surrogate mothers egg, so she will be the legal and the biological mother which may cause some people problems, ethically and morally. Then we have where both of the intended parents are infertile, so a sperm donor is used to make the surrogate mother pregnant, and thirdly we have the gestational surrogate method. This is where the intended mothers egg is fertilized with the intended fathers sperm in a laboratory and then it is placed into the surrogate mother to grow until ready for birth. This method is used because the intended mother either can not carry a baby full term, has had a part hysterectomy, or has other medical reasons that prevent her from becoming pregnant. In the majority of these cases, the surrogate mother will be giving this service due to altruistic reasoning. She will still receive reimbursement for her and her family for any out of pocket expenses she may incur in the 9 months while she is carrying the child'. This amount of money is called the base fee. This is an amount of money that is usually split up into 9 monthly payments. The amounts are never equal in their amounts because of the fact that a miscarriage is more likely in the first three months than at any other time during the pregnancy. So, understandably, the first couple of payments will be less than offered later in the pregnancy so that the intended parents will not have to pay too much for a failed pregnancy but the surrogate mother

A risk-based payment model works to help healthcare providers offer better and more efficient care. Often termed as risk-based payer contracts, this model demands a certain fee from patients that goes to the provider.

The Department of Health and Social Care have retrospectively granted a concessionary price for Isocarboxazid 10mg tablets for the months of May and June 2021. While the reimbursement price had previously been £217.75, a concessionary price of £249.10 has now been granted. The NHS Business Services Authority confirmed that payment for the difference - £31.35 for every pack of 56 claimed - will be adjusted accordingly for the mentionedtime period where contractors have submitted claims in those months. This adjustment will be paid on 31 December 2021 in the next Schedule of Payments.

The Association of the British Pharmaceutical Industry (ABPI) today released a new guidance to pharmaceutical companies using Disclosure UK which it said will boost transparency in the relationships between healthcare professionals, other relevant decision-makers and the industry. The guidance encourages companies to use 'Legitimate Interests' as their lawful basis for processing individual's data, in order to increase the number of named healthcare professionals and other individuals on Disclosure UK, the database showing the payments and benefits in kind made by the pharmaceutical industry to doctors,nurses and other health professionals and organizations. "I'm pleased the ABPI is launching this new guidance which will boost patient safety and public confidence in our healthcare professionals," Patient Safety and Primary Care Minister Maria Caulfield commented.

Two new medications which fight drug-resistant superbugs could soon become available to NHS patients in England after the National Institute for Health and Care Excellence (NICE) said they offered value for money. NICE said Cefiderocol and ceftazidime-avibactam will be the first antimicrobial drugs to be made available as part of a subscription-style payment model that incentivises research and development of antimicrobials by testing new approaches to evaluating and paying for them. As part of part of a project with the NHS and the Department of Health and Social Care, the new payment model is designed to address the growing threat posed by antimicrobial resistance - a serious global problem - which develops when the pathogens that cause infection evolve to make antibiotics and other antimicrobial drugs less effective or stop them from working altogether.

Pharmacy owners can proceed with vaccinating patients who have already scheduled their flu vaccination appointments for September, NHS England has said. However, as announced earlier, the official rollout of the vaccination service will commence from October. Pharmacies will receive compensation for conducting appointments in the upcoming month, NHSE stated in a letter addressed to systems, community pharmacies, and general practices. "Payment for vaccinations will ordinarily only be made following the service commencement date. However, we understand that some firm commitments and appointments have already been made, so where this is the case and the patient wishes to receive flu vaccination in September, NHS England will permit payment claims to be submitted," NHSE said. Care home residents and staff will be eligible for the vaccine starting Oct. 2, while all other patients will commence receiving their vaccinations on Oct 7. This news is a significant relief for pharmacy owners, as they won't have to reschedule appointments due to NHSE's one-month service delay.

Day Lewis Pharmacy has enlisted Locate a Locum, a Belfast-based healthcare technology innovator, to deploy and manage a digital solution aimed at enhancing locum staffing and management across its 267-pharmacy network. "We sought a faster, user-friendly system for instant locum bookings, particularly for last-minute shifts," said Sam Patel, Executive Director at Day Lewis Pharmacy. "This tool improves communication between potential locums and our coordinators, creating more opportunities to attract talent from across the country. Our customers are our priority, and ensuring they have access to staff and advice when needed is our main focus." Locate a Locum will implement a cloud-based digital solution across the Day Lewis Pharmacy estate, allowing locums to securely search, manage, request, and receive payment for shifts, Day Lewis said in a statement. This platform enables locum staff to manage their work diaries, location preferences, and commitments, promoting balanced work-life planning. "The Locate a Locum platform allows for swift, complete payments to our locums and offers them instant booking, eliminating the need for shift confirmation wait times," Patel added. "In a dynamic market with rising demand for pharmacy services, this platform is a game-changer, driving growth and unlocking potential."